Lila Villaros-Sirven

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

Journal: Neurology

Published: January 19, 2022

Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study.

Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study.

Journal: Neuro-oncology

Published: April 06, 2021

SARS-CoV-2 infection in patients with primary central nervous system lymphoma.

SARS-CoV-2 infection in patients with primary central nervous system lymphoma.

Journal: Journal of neurology

Published: September 17, 2020

Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy.

Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy.

Journal: Journal of neurovirology

Published: September 16, 2020

Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.

Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.

Journal: Cancers

Published: July 20, 2020

Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.

Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.

Journal: Scientific reports

Published: July 10, 2020

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients.

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients.

Journal: Journal for immunotherapy of cancer

Published: June 18, 2020

Bevacizumab: Is the lower the better for glioblastoma patients in progression?

Bevacizumab: Is the lower the better for glioblastoma patients in progression?

Journal: Bulletin du cancer

Published: March 23, 2018

Showing 1-8 of 8

Last Updated: 09/26/2026